Oncology Service Line

Codes Discussed: ICD-10-PCS Oncology, ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System), 2026 ICD-10-PCS, ICD-10-PCS Official Guidelines for Coding and Reporting, PCS Index and Tables, Medical and Surgical section, Administration section, Radiation Therapy section, New Technology section, Other Procedures section, Monitoring root operation, Introduction root operation, Transfusion root operation, Insertion root operation, Excision root operation, Resection root operation, Destruction root operation, Drainage root operation, Extraction root operation, Inspection root operation, root operation Extirpation (not used for tumor removal), root operation Brachytherapy, root operation Stereotactic Radiosurgery, Beam Radiation modality, Other Radiation modality, PCS Guideline B3.4b (biopsy followed by definitive treatment coded separately), PCS Guideline B6.1b (radiological markers integral and not coded separately as devices), PCS Guideline D1.b (temporary brachytherapy applicator placement coded separately), table 3E0 (Administration Introduction table), table XW0 (New Technology table for oncology-related drugs and CAR T-cell therapies), table 8E0 (Other Procedures table for robotic-assisted, computer-assisted, and fluorescence-guided procedures), table 0VH (Medical/Surgical Insertion table for prostate and seminal vesicles brachytherapy seed/applicator placement), table DV1 (Radiation Therapy table for prostate brachytherapy), 0FB04ZZ (Incorrect answer choice because left liver lobe was the body part), 0FB04ZX (Incorrect answer choice because left liver lobe was the body part), 0FB24ZZ (Percutaneous endoscopic excision of left liver lobe/no qualifier; definitive excision of malignant liver lesion occupying one-third of left liver lobe), 0FB24ZX (Percutaneous endoscopic excision of left liver lobe, diagnostic; needle biopsy of left liver lobe lesion), 0FT24ZZ (Incorrect answer choice because entire left liver lobe was not removed), 30243G4 (Transfusion of bone marrow from unspecified donor into central vein, percutaneous approach), 30243G0 (Incorrect answer choice because bone marrow did not come from the patient), 30233G1 (Incorrect answer choice because bone marrow was infused through a central, not peripheral, vein), 30240G1 (Incorrect answer choice because bone marrow was infused through central venous catheter without incision), 0HBU0ZZ (Open excision of left breast/no qualifier; re-excision/removal of entire breast mass with margins), 0HBU0ZX (Open excision of left breast, diagnostic; left breast biopsy), 0HTU0ZZ (Incorrect answer choice because entire breast was not removed), 3E0330M (Introduction of antineoplastic monoclonal antibody into peripheral vein, percutaneous approach; nivolumab for liver cancer), 0HBT0ZX (as listed in source answer for hysterectomy/sentinel lymph node biopsy scenario; source appears internally inconsistent with feedback referencing total abdominal hysterectomy), 07B50ZX (as listed in source answer for pelvic sentinel lymph node biopsy), 3E0W3KZ (as listed in source answer for indocyanine green dye injection/sentinel node identification; source feedback also references Monitoring of lymphatic flow), 0UT90ZZ (Total abdominal hysterectomy code shown in answer choices/feedback for hysterectomy scenario), 07BC0ZX (Pelvic lymph node biopsy code shown in answer choices/feedback for hysterectomy scenario), 4A1605H (Monitoring of lymphatic flow with indocyanine green dye as supported by source feedback in sentinel lymph node identification scenario), DV1098Z (High-dose rate prostate brachytherapy with Iridium-192; listed as correct answer line in the source though feedback states the patient received low-dose rate Ir-192), DV10B8Z (Radiation Therapy brachytherapy answer choice; source feedback states this reports brachytherapy but not seed/applicator placement and also states low-dose rate Ir-192), 0VH031Z (Insertion of radioactive element into prostate/seminal vesicles, percutaneous approach; brachytherapy seed placement), 0VH43YZ (Insertion of other device into prostate/seminal vesicles, percutaneous approach; temporary applicator/needle placement for brachytherapy), 02HV33Z (Percutaneous insertion of infusion device into superior vena cava/vascular catheter tip in SVC), 0JH60WZ (Open insertion of totally implantable vascular access device into chest subcutaneous tissue and fascia/port placement), 05HP33Z (Incorrect answer choice because body part should be based on catheter tip location, not external jugular insertion site), 0JH60XZ (Incorrect answer choice because port is totally implantable device, not tunneled vascular access device), D020JZZ (Stereotactic Gamma Beam Radiosurgery of brain/Gamma Knife surgery for brain tumor), D021JZZ (Incorrect answer choice because brain stem was not specified), D01097Z (Incorrect answer choice because Gamma Knife is Stereotactic Radiosurgery, not Brachytherapy), D020DZZ (Incorrect answer choice because Gamma Knife uses Stereotactic Gamma Beam Radiosurgery qualifier), 3E0430P (Introduction of antineoplastic clofarabine into central vein, percutaneous approach; IV Clofarabine through existing vascular access port), 0VB08ZZ (Excision of prostate via natural or artificial opening endoscopic/transurethral resection of part of prostate for prostate cancer), 8E0W8CZ (Robotic-assisted procedure of trunk region via natural or artificial opening endoscopic/da Vinci robotic assistance), 0TJB8ZZ (Inspection of bladder via natural or artificial opening endoscopic/cystourethroscopy/bladder inspection), 0VT08ZZ (Incorrect answer choice because entire prostate was not removed), 0VB08ZX (Incorrect answer choice because procedure was therapeutic, not diagnostic), XW043J7 (Introduction of tisagenlecleucel/KYMRIAH CAR T-cell therapy into central vein, percutaneous approach/New Technology code), 3E0430M (Incorrect answer choice for KYMRIAH because KYMRIAH is New Technology; also antineoplastic monoclonal antibody route context), XW043G7 (Incorrect answer choice because there is a specific substance value for KYMRIAH), XW033J7 (Incorrect answer choice because KYMRIAH was administered through central venous port), qualifier Diagnostic, qualifier No Qualifier, qualifier Y (Hyperthermic for HIPEC), qualifier D (Stereotactic Other Photon Radiosurgery/X-Knife or LINAC-based stereotactic radiosurgery), qualifier H (Stereotactic Particulate Radiosurgery/proton or particle beam radiosurgery), qualifier J (Stereotactic Gamma Beam Radiosurgery/Gamma Knife), Antineoplastic substance value 0, Immunotherapeutic substance, monoclonal antibody qualifier, clofarabine qualifier, high-dose interleukin-2 qualifier, low-dose interleukin-2 qualifier, liquid brachytherapy qualifier, other cancer therapies qualifier, central vein body region, peripheral vein body region, subcutaneous tissue body region, muscle body region, skin and mucous membranes body region, spinal canal body region, peritoneal cavity body region, radioactive element device, other device value Y for temporary brachytherapy applicator, infusion device, vascular access device tunneled, vascular access device totally implantable, superior vena cava, cavoatrial junction, central venous access device, Huber needle, tunneled catheter, port, TIVAD (Totally implantable vascular access device), CAR T-cell therapy, KYMRIAH, nivolumab, Clofarabine, high-dose interleukin-2, low-dose interleukin-2, liquid brachytherapy, HIPEC (Hyperthermic intraperitoneal chemotherapy), LDR (Low-dose rate brachytherapy), HDR (High-dose rate brachytherapy), Iridium-192/Ir-192, Palladium-103, Cobalt-60, LINAC (Linear accelerator), Gamma Knife, X-Knife, CyberKnife, proton beam radiosurgery, photon therapy, neutron capture therapy, orthovoltage x-ray, cobalt-60 machine, da Vinci robot, indocyanine green dye/ICG dye, radioactive tracer, dye, sentinel lymph node, pelvic lymph node, bone marrow transplant, stem cell transplant, blood transfusion, chemotherapy, immunotherapy, biotherapy, biologic therapy, monoclonal antibody, central venous catheter, peripheral vein, central vein, intrathecal chemotherapy, intraperitoneal chemotherapy, subarachnoid space, arachnoid, pia mater, blood brain barrier, peritoneal cavity, breast biopsy, breast mass excision, liver lesion biopsy, malignant liver lesion excision, cholecystectomy context not coded in CP2, hysterectomy context, total abdominal hysterectomy, prostate brachytherapy, brachytherapy seeds, hollow needles, afterloader/autoloader, vascular access port placement, external jugular vein access, prostate cancer TURP, transurethral resection of prostate, cystourethroscopy, bladder neck, prostate left lobe and right lobe resection, well-differentiated breast carcinoma, leukemia, ALL (Acute lymphoblastic leukemia), B-cell non-Hodgkin lymphoma, ovarian cancer, liver cancer, prostate cancer, brain tumor, breast carcinoma, malignant pleural effusion, thoracentesis, D&C (Dilation and curettage), endometrial biopsy, radiological marker, needle localization, pathological diagnosis, clear margins, intraoperative pathological diagnosis.

Topics Covered: ICD-10-PCS Oncology Service Line, ICD-10-PCS oncology procedure coding, oncology inpatient procedure coding, cancer procedure coding, malignancy procedure coding, surgical treatment of malignancies, infusion procedures for neoplastic disease, radiation therapy coding, oncology Code Red challenge, cancer overview, uncontrolled abnormal cell growth, tumor formation, leukemia without tumor mass, carcinoma, sarcoma, leukemia, lymphoma, central nervous system cancer, skin cancer, internal organ lining cancer, bone cancer, cartilage cancer, fat cancer, muscle cancer, connective tissue cancer, blood cancer, bone marrow cancer, immune system cancer, brain cancer, spinal cord cancer, tumor removal coding, cancerous lesion coding, neoplasm surgery coding, Excision versus Resection, tumor as body part tissue, Extirpation not used for tumor removal, solid matter versus body part distinction, partial body part removal, complete body part removal, diagnostic qualifier use, biopsy coding, biopsy followed by definitive treatment, clear margin excision, multiple procedure coding guideline, Drainage in oncology procedures, Extraction in oncology procedures, Destruction of neoplastic lesion, malignant pleural effusion evaluation, diagnostic thoracentesis, therapeutic thoracentesis, no qualifier for therapeutic drainage, dilation and curettage for endometrial biopsy, D&C oncology coding, sentinel lymph node biopsy coding, sentinel node identification, lymphatic spread of cancer, metastatic cancer diagnosis, lymph node biopsy, lymphatic drainage pattern identification, radioactive tracer injection, dye injection, indocyanine green dye, ICG dye, lymphatic flow monitoring, sentinel node removal, biopsy of pelvic lymph nodes, hysterectomy with sentinel lymph node biopsy, robotic-assisted oncology surgery, computer-assisted oncology surgery, fluorescence-guided surgery, optical imaging technology, intraoperative tumor identification, tumor margin identification, Other Procedures section add-on coding, vascular access devices for oncology, adjuvant therapy access, chemotherapy access, tunneled catheter coding, port coding, totally implantable vascular access device coding, central venous catheter coding, superior vena cava catheter tip, cavoatrial junction catheter tip, catheter tip location coding, vascular portion of port placement, subcutaneous portion of port placement, open pocket creation, percutaneous vascular access, ovarian cancer port placement case, external jugular vein access, catheter tunneled under skin, chemotherapy coding, systemic cancer treatment, chemo as antineoplastic therapy, intravenous chemotherapy, central vein chemotherapy, peripheral vein chemotherapy, arterial chemotherapy, intramuscular chemotherapy, subcutaneous chemotherapy, intrathecal chemotherapy, intraperitoneal chemotherapy, topical chemotherapy, oral chemotherapy, blood brain barrier, central nervous system cancer chemotherapy, spinal canal body region, subarachnoid space, arachnoid layer, pia mater layer, immunotherapy coding, biotherapy coding, biologic therapy coding, immune system cancer treatment, white blood cell immune response, immunotherapy versus chemotherapy, antineoplastic substance selection, immunotherapeutic substance selection, cancer versus noncancer condition substance selection, antineoplastic monoclonal antibody coding, monoclonal antibody for liver cancer, nivolumab therapy, clofarabine chemotherapy, ALL chemotherapy, vascular access port infusion, Huber needle access, high-dose interleukin-2 therapy, low-dose interleukin-2 therapy, liquid brachytherapy classification, other cancer therapy qualifier, Administration section coding, Introduction root operation, PCS table 3E0, body region based on route of administration, approach selection in Introduction table, open approach versus percutaneous approach, substance character selection, qualifier character for antineoplastic drugs, hyperthermic intraperitoneal chemotherapy, HIPEC coding, peritoneal cancer treatment, heated concentrated chemotherapy, microscopic residual cancer cell destruction, peritoneal cavity body part, hyperthermic qualifier, New Technology oncology coding, table XW0, CAR T-cell therapy coding, IPPS new technology add-on payment, generic name versus trade name, Substance Key use, KYMRIAH coding, tisagenlecleucel, refractory aggressive B-cell non-Hodgkin lymphoma, central port CAR-T administration, transfusion therapy, blood transfusion coding, cancer-related anemia treatment, stem cell transplant coding, bone marrow transplant coding, Transfusion root operation, donor bone marrow administration, central venous catheter transfusion, peripheral versus central vein transfusion, blood product specificity, leukemia failed chemotherapy bone marrow transplant case, Radiation Therapy section coding, radiation oncology coding, radiation therapy modalities, localized cancer treatment, high-energy particles, high-energy waves, radiation dose planning, surrounding tissue preservation, Radiation Therapy code structure, Radiation Therapy first character D, body system character, radiation modality character, treatment site character, modality qualifier character, isotope character, qualifier character, beam radiation coding, teletherapy coding, external beam radiation coding, linear accelerator coding, LINAC, low-energy photon therapy, high-energy photon therapy, photon beam dosage, milli-electron volts, MeVs, heavy particle therapy, proton therapy, ion therapy, neutron therapy, electron therapy, neutron capture therapy, NCT two-step procedure, neutron capture agent, tumor destruction by nuclear reaction, brachytherapy coding, traditional brachytherapy, interstitial brachytherapy, intracavitary brachytherapy, liquid brachytherapy, systemic brachytherapy, brachytherapy seed placement, radioactive seed insertion, radioactive ribbons, hollow needle applicator placement, permanent brachytherapy seeds, temporary brachytherapy delivery, high-dose rate brachytherapy, low-dose rate brachytherapy, radioactive element device, temporary applicator coding, prostate brachytherapy, prostate and seminal vesicles body part, Iridium-192 brachytherapy, palladium-103 unidirectional source, bioabsorbable membrane brachytherapy source, flexible radioactive membrane, seed placement plus radiation therapy coding, Medical and Surgical section for brachytherapy seed placement, Radiation Therapy section for radiation dose delivery, stereotactic radiosurgery coding, 3D tumor reconstruction, computer-guided radiation targeting, no-incision radiosurgery, brain tumor radiosurgery, Gamma Knife procedure, Cobalt-60 sources, helmet focusing, head frame immobilization, LINAC-based radiosurgery, X-Knife procedure, CyberKnife procedure, particle-based radiosurgery, proton beam radiosurgery, stereotactic gamma beam radiosurgery qualifier, stereotactic other photon radiosurgery qualifier, stereotactic particulate radiosurgery qualifier, Other Radiation modality, breast biopsy root operation, needle localization, radiological guidance marker, radiological marker integral coding, breast lesion excision, liver lesion biopsy and excision case, malignant left liver lobe lesion, definitive procedure sequencing, principal procedure sequencing, breast carcinoma biopsy and margin re-excision case, well-differentiated breast carcinoma, clear margin confirmation, procedure with distinct objectives, hysterectomy with sentinel lymph node biopsy case, pelvic sentinel nodes, total abdominal hysterectomy answer feedback, prostate cancer brachytherapy case, LDR Ir-192 seed delivery, autoloader/afterloader applicator, ultrasound-guided prostate needle placement, Gamma Knife brain tumor case, transurethral prostate resection for prostate cancer, TURP coding, da Vinci robotic-assisted TURP, cystoscopy suite procedure, cystourethroscopy inspection, resectoscope, bladder neck opening, prostate lobe resection, therapeutic prostate excision, diagnostic qualifier not used for treatment, Code Purple practice, Code Red Ultimate Challenge, chemotherapy route matching, IV via central venous port to central vein, subcutaneous chemotherapy to subcutaneous tissue, intramuscular chemotherapy to muscle, topical chemotherapy to skin and mucous membranes, intrathecal chemotherapy to spinal canal, substance classification matching, clofarabine as chemotherapy, interleukin-2 as immunotherapy, monoclonal antibody as immunotherapy, liquid brachytherapy as other cancer therapy, transfusion and bone marrow transplant section quiz, X-Knife modality qualifier quiz, bone marrow transplant case, liver cancer nivolumab case, ovarian cancer vascular access port case, ALL clofarabine infusion case, CAR T-cell KYMRIAH case, oncology coding education, ICD-10-PCS inpatient procedure coding education, medical coding course content